Women are the fastest-growing demographic in cannabis. Female cannabis use has increased by over 50% since 2019, and women now account for approximately 40% of all cannabis consumers in legal markets. Yet the overwhelming majority of cannabis research has been conducted on male subjects — both human and animal — creating a massive knowledge gap in how cannabinoids interact with female physiology.

This gap matters because women do not simply use cannabis the same way men do in a slightly smaller body. Women have fundamentally different endocannabinoid system expression, different THC metabolism, different hormonal interactions with cannabinoids, and different reported reasons for use. The female reproductive system is one of the most endocannabinoid-rich systems in the body, with CB1 and CB2 receptors densely expressed in the uterus, ovaries, fallopian tubes, and mammary tissue.

Here is what the research actually shows — the genuine findings, the promising directions, and the significant limitations — about cannabis and women’s health.

Sex Differences in Cannabis Pharmacology

Before discussing specific health conditions, it is essential to understand that women and men process cannabis differently at a basic pharmacological level.

THC metabolism: Women generally have higher body fat percentages than men, and THC is highly lipophilic (fat-soluble). This means women tend to store more THC in adipose tissue, which can affect both the duration of effects and the timeline of THC elimination from the body. Women may test positive on drug tests for longer periods after the same level of use.

Hormonal interactions: Estrogen modulates the endocannabinoid system. Research has shown that estradiol (the primary form of estrogen) increases anandamide synthesis and CB1 receptor expression. This means the endocannabinoid system fluctuates across the menstrual cycle — ECS activity is higher during the follicular phase (when estrogen is rising) and lower during the luteal phase (when progesterone dominates).

Sensitivity and tolerance: Animal studies suggest that females develop tolerance to THC more quickly than males but are also more sensitive to THC at lower doses. A 2014 study in Drug and Alcohol Dependence found that women reported stronger subjective effects from the same THC dose relative to body weight.

Biphasic response: Women appear to have a more pronounced biphasic dose-response curve. Low doses of THC tend to produce more positive effects (relaxation, mood elevation) while high doses are more likely to produce anxiety and dysphoria in women compared to men. This has direct implications for dosing recommendations.

Menstrual Pain and Dysmenorrhea

Menstrual pain is the single most commonly reported reason women use cannabis for health purposes. A 2022 survey published in the Journal of Women’s Health found that 86% of women who use cannabis for menstrual symptoms reported it was effective for pain relief.

The biological rationale is strong. The endometrium (uterine lining) is rich in CB1 receptors, and endocannabinoid levels in the uterus fluctuate dramatically across the menstrual cycle. During menstruation, prostaglandin release triggers uterine contractions — the mechanism of menstrual cramps. Cannabinoids, particularly THC and CBD, have well-documented anti-prostaglandin activity. They inhibit the COX-2 enzyme pathway — the same pathway targeted by NSAIDs like ibuprofen.

What the studies show:

A 2023 randomized, placebo-controlled study published in BMJ Sexual & Reproductive Health evaluated a THC/CBD combination product for primary dysmenorrhea. The study found a statistically significant reduction in pain scores compared to placebo, with the highest effect size during the first 4 hours of use. However, the study was small (n=63) and used a specific formulation, limiting generalizability.

Survey data is consistently positive. A 2020 study of 1,087 women in the Journal of Obstetrics and Gynaecology Canada found that 85% of those who used cannabis for menstrual symptoms reported improvement, with inhaled cannabis rated more effective than oral products due to faster onset.

Practical considerations: Many women report that CBD-dominant products (ratios of 4:1 CBD:THC or higher) provide sufficient pain relief for mild-to-moderate cramps without significant psychoactive effects. For severe dysmenorrhea, products combining THC and CBD appear to be more effective than either cannabinoid alone. Topical products applied to the lower abdomen are increasingly popular, though clinical data on this delivery method is limited.

Endometriosis

Endometriosis affects approximately 10% of women of reproductive age — an estimated 190 million worldwide. It is a chronic inflammatory condition in which tissue similar to the uterine lining grows outside the uterus, causing severe pain, adhesions, and often infertility. Current treatments (hormonal suppression, surgical excision) have significant limitations and side effects, creating substantial demand for alternative approaches.

The endocannabinoid connection to endometriosis is one of the most compelling in women’s health research. Multiple studies have documented that women with endometriosis have altered endocannabinoid system function — specifically, lower levels of CB1 receptors in endometrial tissue, potentially contributing to the pain sensitization that characterizes the condition.

A 2010 study in the journal Pain demonstrated that CB1 receptor agonists reduced the growth of endometriotic implants and associated pain in a rat model. The mechanism appears to involve both anti-inflammatory effects (reducing the immune dysregulation that drives endometrial tissue growth) and direct pain modulation (reducing the nerve sensitization caused by endometriotic lesions).

A large-scale survey published in 2021 in PLOS ONE found that among women with endometriosis who used cannabis, the most commonly reported benefits were pain reduction (56%), improved sleep (50%), and reduced nausea (48%). Notably, cannabis was rated as more effective than many prescription medications, including hormonal therapies and opioids, though this is self-reported and subject to bias.

No randomized controlled trial has yet been published specifically evaluating cannabis for endometriosis. Multiple trials are registered and underway as of 2026. The preclinical evidence is strong enough that several major endometriosis patient advocacy organizations have called for accelerated research.

Polycystic Ovary Syndrome (PCOS)

PCOS affects 6-12% of women of reproductive age and is characterized by hormonal imbalance, insulin resistance, chronic low-grade inflammation, and metabolic dysfunction. The endocannabinoid system is increasingly implicated in PCOS pathophysiology.

Women with PCOS have been found to have elevated circulating endocannabinoid levels (particularly anandamide and 2-AG) compared to women without PCOS. This elevation correlates with insulin resistance and is independent of body weight. The ECS is deeply integrated with metabolic regulation, and some researchers hypothesize that endocannabinoid system dysregulation may be both a consequence and a driver of PCOS.

Implications for cannabis use in PCOS are complex. THC activates CB1 receptors, which in peripheral tissues can exacerbate insulin resistance — potentially worsening a core feature of PCOS. However, CBD has been shown to improve insulin sensitivity in animal models and human studies. THCV (tetrahydrocannabivarin) has demonstrated particularly promising effects on insulin sensitivity and metabolic function in early clinical trials.

The current evidence does not support recommending cannabis as a PCOS treatment, but it does suggest that cannabinoid medicine — particularly CBD and THCV — deserves investigation. Women with PCOS who use THC-dominant cannabis should be aware of the potential metabolic implications.

Menopause

Menopause represents one of the most significant shifts in endocannabinoid system function that occurs in a woman’s lifetime. The decline in estrogen that defines menopause directly reduces CB1 receptor expression and endocannabinoid tone throughout the body. This decline may contribute to several hallmark menopausal symptoms.

Hot flashes: The thermoregulatory system is modulated by the endocannabinoid system. CB1 receptors in the hypothalamus (the brain’s temperature control center) participate in temperature regulation. Some researchers hypothesize that the decline in endocannabinoid tone during menopause destabilizes thermoregulation, contributing to hot flashes. Anecdotal reports of cannabis reducing hot flash frequency are widespread, but no controlled trial has been published.

Sleep disturbance: Menopause-related sleep disruption affects approximately 40-60% of menopausal women. THC has demonstrated sleep-promoting effects in multiple contexts, and a 2023 survey of menopausal cannabis users found that 67% reported improved sleep quality. CBD may also improve sleep independently of THC, though the evidence is mixed.

Bone density: Postmenopausal osteoporosis is a major health concern. Both CB1 and CB2 receptors are expressed on osteoblasts (bone-building cells) and osteoclasts (bone-resorbing cells). CBD has shown potential to promote bone healing and reduce bone resorption in preclinical models. A 2015 study in the Journal of Bone and Mineral Research found that CB2 receptor activation protected against age-related bone loss in mice. Whether these findings translate to humans is unknown.

Mood and anxiety: The decline in endocannabinoid tone during menopause may contribute to the increased rates of anxiety and depression seen during the menopausal transition. Low-dose THC and CBD have both shown anxiolytic properties, and survey data consistently shows mood improvement as one of the primary reasons menopausal women use cannabis.

A 2022 study in Menopause: The Journal of the North American Menopause Society found that 79% of menopausal or perimenopausal women who used cannabis reported that it helped with at least one menopausal symptom. The most commonly cited benefits were sleep improvement (67%), mood improvement (46%), and reduction in anxiety (42%). Only 4% of respondents reported negative effects.

Fertility and Conception

The intersection of cannabis and fertility is one of the most contentious topics in women’s health. The endocannabinoid system plays critical roles in ovulation, embryo implantation, and early pregnancy maintenance, raising legitimate concerns about cannabis use during conception attempts.

What the research shows:

Endocannabinoid levels in the uterus must be precisely regulated for successful embryo implantation. Both too much and too little anandamide can prevent implantation. Exogenous cannabinoids like THC can disrupt this delicate balance. A 2019 study in the American Journal of Obstetrics and Gynecology found that cannabis use was associated with a 41% reduction in fecundability (the probability of conceiving in a given cycle) among women trying to conceive.

However, a large prospective study published in 2021 (the PRESTO study) found no significant association between female cannabis use and time to pregnancy after adjusting for confounding factors like alcohol and tobacco use. The mixed results may reflect dose-dependent effects — occasional use may not meaningfully impact fertility, while daily use may.

The ovarian reserve: THC has been shown to affect gonadotropin-releasing hormone (GnRH) signaling, which controls the release of FSH and LH — the hormones that regulate ovulation. Chronic THC exposure can delay or suppress ovulation in some women. However, these effects appear to be reversible upon cessation.

Practical recommendation: While the evidence is mixed, the precautionary principle suggests that women actively trying to conceive should minimize or eliminate cannabis use. The stakes are high, the evidence of safety is insufficient, and the potential mechanisms of harm are biologically plausible.

Pregnancy and Breastfeeding

Cannabis use during pregnancy is an area where the medical consensus is clear: it is not recommended. This position is held by the American College of Obstetricians and Gynecologists (ACOG), the American Academy of Pediatrics (AAP), and every major medical organization that has issued guidance.

THC crosses the placental barrier and reaches the fetus. Animal studies have demonstrated that prenatal THC exposure affects neurodevelopment, particularly in endocannabinoid system maturation, which plays a critical role in fetal brain development. Human observational studies have associated prenatal cannabis exposure with lower birth weight, preterm delivery, and subtle neurodevelopmental differences in childhood (particularly in attention and executive function).

THC is also secreted into breast milk. Studies have detected THC in breast milk up to 6 days after the last use, with concentrations that could deliver a meaningful dose to an infant. The infant endocannabinoid system is actively developing and highly sensitive to exogenous cannabinoids.

CBD has not been adequately studied in pregnancy, and the absence of evidence of harm is not evidence of absence. No CBD product has been proven safe for use during pregnancy.

For nausea during pregnancy: Despite the documented antiemetic properties of cannabis, the risks during pregnancy outweigh the benefits. First-line treatments for hyperemesis gravidarum (severe pregnancy nausea) include doxylamine, pyridoxine (vitamin B6), and ondansetron — all of which have more established safety profiles in pregnancy.

Breast Cancer

The endocannabinoid system’s role in breast cancer biology has been studied extensively in preclinical models with genuinely intriguing results.

CBD has demonstrated anti-proliferative, pro-apoptotic (promoting cancer cell death), and anti-metastatic effects in multiple breast cancer cell lines in laboratory settings. A 2019 study in the International Journal of Molecular Sciences showed that CBD inhibited the growth of triple-negative breast cancer cells (an aggressive subtype with limited treatment options) and reduced their ability to migrate and invade surrounding tissue.

THC has also shown anti-tumor effects in breast cancer models, though through different mechanisms — primarily by inducing autophagy (cellular self-destruction) in cancer cells while leaving healthy cells relatively unaffected.

However: These are preclinical findings. No randomized controlled trial has demonstrated that cannabis or cannabinoids can treat, cure, or prevent breast cancer in humans. The doses used in laboratory studies often exceed what can be achieved through normal cannabis consumption. Cannabis should never be used as a substitute for evidence-based cancer treatment.

Where cannabis has established clinical value in breast cancer is in symptom management during chemotherapy — particularly for nausea, pain, appetite loss, and anxiety. FDA-approved synthetic cannabinoids (dronabinol, nabilone) are already used for chemotherapy-induced nausea, and many oncologists are supportive of medical cannabis use as a complementary approach during treatment.

Moving Forward: What Women Need From Cannabis Research

The most pressing need in cannabis and women’s health research is simple: inclusion. Women must be adequately represented in clinical trials, and sex-stratified data must be reported as standard practice. The historical bias toward male subjects in cannabis research has left women navigating their health decisions with inadequate evidence.

Specific research priorities include:

  • Randomized controlled trials of cannabis for endometriosis pain
  • Longitudinal studies of cannabinoid use during the menopausal transition
  • Investigation of sex-specific dosing guidelines
  • Fertility studies that control for dose, frequency, and cannabinoid ratios
  • Safety data on CBD use during pregnancy and breastfeeding
  • The role of the endocannabinoid system in PCOS pathophysiology

Until this research is completed, women using cannabis for health purposes are making decisions based on limited evidence, survey data, and personal experimentation. That is not ideal — but it is the reality created by decades of cannabis prohibition and research restrictions. The best any individual can do is understand what the current science shows, what it does not show, and make informed decisions accordingly.